BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/22/2022 6:17:12 AM | Browse: 280 | Download: 361
Publication Name World Journal of Clinical Oncology
Manuscript ID 62012
Country/Territory Spain
Received
2020-12-25 21:37
Peer-Review Started
2020-12-25 21:38
To Make the First Decision
Return for Revision
2021-09-29 10:28
Revised
2021-10-05 19:35
Second Decision
2022-01-10 05:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-01-10 22:58
Articles in Press
2022-01-10 22:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
2022-01-05 11:08
Typeset the Manuscript
2022-01-17 13:15
Publish the Manuscript Online
2022-01-22 06:17
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Update on the treatment of metastatic renal cell carcinoma
Manuscript Source Invited Manuscript
All Author List Rafael Antonio Medina López, Ines Rivero Belenchon, Javier Mazuecos-Quirós, Carmen Belén Congregado-Ruíz and Felipe Couñago
ORCID
Author(s) ORCID Number
Rafael Antonio Medina López http://orcid.org/0000-0002-4514-4329
Ines Rivero Belenchon http://orcid.org/000-0002-6217-4618
Javier Mazuecos-Quirós http://orcid.org/0000-0001-5338-7526
Carmen Belén Congregado-Ruíz http://orcid.org/0000-0001-8801-0614
Felipe Couñago http://orcid.org/0000-0001-7233-0234
Funding Agency and Grant Number
Corresponding Author Ines Rivero Belenchon, MD, Staff Physician, Department of Urology and Nephrology, Virgen del Rocío University Hospital, Manuel Siurot s/n, Seville 41005, Spain. ines.rivero.belenchon@gmail.com
Key Words Metastatic renal cell carcinoma; Systemic treatment; Immune checkpoint inhibitors; Antiangiogenic; Update; Biomarkers
Core Tip Kidney cancer therapeutics is a fast-changing field, and the outcome of metastatic renal cell carcinoma (mRCC) has thus improved considerably in recent years with the introduction of different combinations of immune checkpoint and vascular endothelial growth factors inhibitors. State-of-the-art systemic therapy regimens must be addressed to be in a position to offer patients the best options. The aim of this editorial is to provide an update and insight on future directions on mRCC management.
Publish Date 2022-01-22 06:17
Citation Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. World J Clin Oncol 2022; 13(1): 1-8
URL https://www.wjgnet.com/2218-4333/full/v13/i1/1.htm
DOI https://dx.doi.org/10.5306/wjco.v13.i1.1
Full Article (PDF) WJCO-13-1.pdf
Full Article (Word) WJCO-13-1.docx
Manuscript File 62012_Auto_Edited-JJW-WangTQ.docx
Answering Reviewers 62012-Answering reviewers.pdf
Audio Core Tip 62012-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 62012-Conflict-of-interest statement.pdf
Copyright License Agreement 62012-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 62012-Language certificate.pdf
Peer-review Report 62012-Peer-review(s).pdf
Scientific Misconduct Check 62012-Bing-Wang JJ-2.png
Scientific Editor Work List 62012-Scientific editor work list.pdf